miR-34a Is an Intracellular and Exosomal Predictive Biomarker for Response to Docetaxel With Clinical Relevance to Prostate Cancer Progression

Prostate - United States
doi 10.1002/pros.22848
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Wiley

Related search

Endotrophin, a Multifaceted Player in Metabolic Dysregulation and Cancer Progression, Is a Predictive Biomarker for the Response to PPARγ Agonist Treatment

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Predictive Relevance of miR‑34a, miR‑224 and miR‑342 in Patients With Advanced Squamous Cell Carcinoma of the Lung Undergoing Palliative Chemotherapy

Oncology Letters
Cancer ResearchOncology
2017English

Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-Resistant Prostate Cancer

European Urology
Urology
2015English

Prostate Apoptosis Response-4 Is Involved in the Apoptosis Response to Docetaxel in McF-7 Breast Cancer Cells

International Journal of Oncology
Cancer ResearchOncology
2013English

miR‑320a Is an Independent Prognostic Biomarker for Invasive Breast Cancer

Oncology Letters
Cancer ResearchOncology
2014English

Salvage Therapy for Castration-Refractory Prostate Cancer Resistant to Docetaxel

Japanese Journal of Urology
Urology
2013English

miR-34a Expression in Human Breast Cancer Is Associated With Drug Resistance

Oncotarget
Oncology
2017English

Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

Insulin-Like Growth Factor-I Induces Chemoresistence to Docetaxel by Inhibiting miR-143 in Human Prostate Cancer

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy